STOCKHOLM, Oct. 23, 2019 /PRNewswire/ -- On 31 October, at
08:00 CET, Swedish Orphan Biovitrum
AB (publ) (Sobi™) will publish its report for the third quarter
2019. Financial analysts and media are invited to participate in a
telephone conference, which will include a presentation of the
results, on the same day at 10:00 am CET. The
event will be hosted by Sobi's CEO and President, Guido Oelkers, and the presentation will be held
in English.
The presentation can be followed live, or afterwards on
www.sobi.com. Slides used in the presentation will be made
available on Sobi's website prior to the telephone conference.
To participate in the telephone conference, please call:
SE: +46-8-505-583-55
UK: +44-333-300-92-66
US: +1-646-722-49-02
Click here to go to the live webcast.
After the live event the webcast will be available on-demand
via the same URL.
About Sobi™
Sobi is a specialised international biopharmaceutical company
transforming the lives of people with rare diseases. Sobi is
providing sustainable access to innovative therapies in the areas
of haematology, immunology and specialty indications. Today, Sobi
employs approximately 1,300 people across Europe, North
America, the Middle East,
Russia and North Africa. In 2018, Sobi's revenues
amounted to SEK 9.1 billion. Sobi's
share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more
information about Sobi at sobi.com.
For more information please contact
Paula Treutiger
Head of Communication & Investor Relations
+46-733-666-599
paula.treutiger@sobi.com
Linda Holmström
Corporate Communication & Investor Relations
+46-708-734095
linda.holmstrom@sobi.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/invitation---presentation-of-sobi-s-q3-2019-results,c2939150
The following files are available for download:
https://mb.cision.com/Main/14266/2939150/1128077.pdf
|
Invitation to
presentation of Sobi's Q3 2019 results
|
View original
content:http://www.prnewswire.com/news-releases/invitation--presentation-of-sobis-q3-2019-results-300943769.html
SOURCE Swedish Orphan Biovitrum AB